Table 3. Crude odds ratio (OR) and 95% confidence intervals (CI) for residual disease six months after cryotherapy (cryo) for CIN2/3 by persistence of hrHPV infections detected in pre-cryo cells or biopsies.
| Persistence ofhrHPV | Total n | Cured (≤LSIL/CIN1) n (%) | Residual disease(CIN2/3) n (%) | OR (95% CI) |
| Pre-cryo cells | ||||
| No | 12 | 11 (25.6) | 1 (5.6) | 1 |
| Yes | 49 | 32 (74.4) | 17 (94.4) | 5.8 (0.7–49.2) |
| Pre-cryo biopsies 1 | ||||
| No | 11 | 10 (32.3) | 1 (5.6) | 1 |
| Yes | 38 | 21 (67.7) | 17 (94.4) | 8.1 (0.9–69.7) |
Kenya, 61 HIV-positive women.
1
Does not include 12 women who were hrHPV-positive in cells but negative in biopsy.
hrHPV, high-risk human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; CIN, cervical intraepithelial neoplasia.